Stock Market Reviews

Read and share opinions on DXCM (DexCom, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential
  Dec 22, 2025
• Investors in DexCom (NASDAQ:DXCM) have unfortunately lost 43% over the last three years
  Dec 18, 2025
• Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
  Dec 17, 2025

DXCM News

• 1 Cash-Heavy Stock for Long-Term Investors and 2 We Avoid
  Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
  Dec 23, 2025
• Medtronic’s diabetes spinoff MiniMed files for IPO
  MiniMed is pitching the breadth of its portfolio as an advantage over more focused rivals such as Dexcom and Insulet.
  Dec 22, 2025
• 3 Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025
  As the United States market kicks off a holiday-shortened week, major stock indexes like the S&P 500, Nasdaq, and Dow Jones Industrial Average have shown gains, buoyed by advances in tech shares and record highs in gold and silver. Amidst this positive momentum, investors are keenly focused on identifying stocks that may be trading below their intrinsic value, presenting potential opportunities for those looking to capitalize on undervalued assets.
  Dec 22, 2025
• Morgan Stanley Upgrades DexCom (DXCM), Cites Undervalued Recovery and G7 Margin Potential
  DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from $63. The firm noted that the company is overcoming recent operational hurdles while its stock remains at historical lows. […]
  Dec 22, 2025
• Undervalued Equities That May Offer Value In December 2025
  As the U.S. stock market experiences a resurgence with major indexes posting gains, driven by a rally in tech stocks, investors are increasingly looking for opportunities that may be undervalued. In this environment of renewed risk appetite and shifting sector performances, identifying stocks that offer strong fundamentals at attractive valuations becomes crucial for those seeking potential value in their portfolios.
  Dec 22, 2025
• Why Jabil (JBL) Stock Is Trading Up Today
  Shares of electronics manufacturing services provider Jabil (NYSE:JBL) jumped 3.5% in the morning session after an analyst reiterated a Strong Buy rating on the stock, coupled with the company's forecast for strong annual results. Investment firm Raymond James reaffirmed its positive stance and directly addressed market rumors, stating that claims of Jabil losing business with client Dexcom were "categorically NOT happening." This statement appeared to boost investor confidence.
  Dec 19, 2025
• 1 Cash-Producing Stock with Impressive Fundamentals and 2 We Ignore
  While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
  Dec 19, 2025
• 3 Stocks Estimated To Be Undervalued By Up To 48.3%
  As the U.S. stock market experiences a resurgence, with major indices like the Nasdaq and S&P 500 seeing notable gains driven by tech shares, investors are keenly observing opportunities that may arise from these fluctuations. In such an environment, identifying undervalued stocks can be crucial for those looking to capitalize on potential growth while maintaining a balanced portfolio amidst shifting market dynamics.
  Dec 19, 2025
• 3 Stocks Estimated To Trade At Discounts Of Up To 49.7%
  As the U.S. stock market experiences a notable downturn, with major indexes like the S&P 500 and Dow Jones Industrial Average posting consecutive losses amid tech sector retreats and AI bubble concerns, investors are increasingly on the lookout for opportunities in undervalued stocks. In such turbulent times, identifying stocks that are trading at significant discounts can offer potential value, especially when broader market conditions have led to price corrections across various sectors.
  Dec 19, 2025
• 3 Stocks Estimated To Be Up To 36.7% Below Intrinsic Value Offering Potential Opportunities
  In recent market developments, the S&P 500 and Dow Jones Industrial Average have experienced declines following a surprising rise in unemployment, while the Nasdaq managed to tick higher, breaking its losing streak. Amid these mixed signals from major indices and economic indicators, investors may find opportunities in stocks that are perceived to be undervalued relative to their intrinsic value. Identifying such stocks requires careful analysis of financial health and growth potential within...
  Dec 18, 2025
• DexCom (DXCM) Fell Due to Modest Guidance
  Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy underperformed its benchmark, the Russell Midcap® Growth Index, in the third quarter of 2025, which increased approximately 3%. In addition, please check the fund’s top five holdings […]
  Dec 18, 2025
• December 2025's Stock Selections Estimated To Be Priced Below Fair Value
  As the U.S. stock market rebounds with major indices like the Dow Jones and S&P 500 poised to break their recent losing streaks, investors are closely monitoring inflation trends that have come in lower than expected. In this environment of fluctuating economic indicators, identifying stocks that may be undervalued can offer potential opportunities for those looking to capitalize on discrepancies between current prices and perceived fair value.
  Dec 18, 2025
• Investors in DexCom (NASDAQ:DXCM) have unfortunately lost 43% over the last three years
  DexCom, Inc. ( NASDAQ:DXCM ) shareholders should be happy to see the share price up 12% in the last month. But that...
  Dec 18, 2025
• Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
  DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
  Dec 17, 2025
• Blood Glucose Monitor Market Set to Reach USD 25.4 Billion by 2030 with a CAGR of 9.1%
  The global blood glucose monitor market is set to expand from USD 16.5 billion in 2025 to USD 25.4 billion by 2030, growing at a CAGR of 9.1%. This growth is fueled by the increasing prevalence of diabetes, a rising geriatric population, and enhanced self-monitoring awareness. Technological advancements in continuous glucose monitoring (CGM), smartphone integration, and AI data analytics have boosted accuracy and patient engagement. The self-monitoring blood glucose systems segment leads in mark
  Dec 17, 2025
• December 2025's Top Stocks Estimated Below Intrinsic Value
  As December 2025 unfolds, the U.S. stock market faces a challenging period with major indices like the S&P 500 and Dow Jones Industrial Average experiencing consecutive declines amid AI bubble concerns and rising unemployment rates. In such an environment, identifying undervalued stocks becomes crucial for investors seeking opportunities that may offer potential value relative to their intrinsic worth.
  Dec 17, 2025
• 3 Stocks Estimated To Be Trading At Discounts Of 23.8% To 35.3%
  As the United States stock market grapples with concerns over an AI bubble and fluctuating major indexes, investors are keenly observing economic indicators like the upcoming jobs report to gauge future market directions. In this environment of uncertainty, identifying stocks that are potentially undervalued can offer opportunities for those looking to capitalize on price discrepancies; such stocks may be trading at significant discounts relative to their intrinsic value, providing a...
  Dec 17, 2025
• Discover December 2025's Top Stocks Estimated Below Intrinsic Value
  As the U.S. stock market experiences a retreat following delayed jobs data and higher-than-expected unemployment rates, investors are closely monitoring economic indicators and Federal Reserve decisions for future guidance. In such an environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to invest wisely amid market fluctuations.
  Dec 16, 2025
• 3 Stocks Estimated To Be Trading At Discounts Of Up To 21.1%
  As concerns about an AI bubble continue to weigh on technology stocks, major U.S. indexes have recently closed lower, reflecting investor caution amid looming economic indicators such as the upcoming jobs report. In this climate of uncertainty, identifying undervalued stocks can be a strategic approach for investors looking to capitalize on potential market inefficiencies and secure positions in companies trading at discounts.
  Dec 16, 2025
• Jim Cramer on DexCom: “It’s Too Rich a Stock”
  DexCom, Inc. (NASDAQ:DXCM) is one of the stocks on Jim Cramer’s radar recently. A caller asked if they should buy, sell, or hold the stock during the lightning round. In response, Cramer said: “You know, it’s too rich a stock, and I do think the GLP-1s are going to have such a dramatic effect on […]
  Dec 13, 2025
• DLocal And 2 Other Stocks That May Be Priced Below Intrinsic Value
  As the United States market remains mixed ahead of a highly anticipated Federal Reserve decision on interest rates, investors are keenly observing how these shifts might impact stock valuations. In this environment, identifying stocks that may be priced below their intrinsic value can offer opportunities for those looking to capitalize on potential market inefficiencies.
  Dec 10, 2025
• 3 Prominent Stocks Estimated To Be Trading At Up To 38.4% Below Intrinsic Value
  As U.S. investors keenly await the Federal Reserve's decision on interest rates, major indices like the S&P 500 have recently pulled back after nearing record highs, reflecting a cautious market sentiment. In such an environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to capitalize on potential undervaluation amidst broader economic uncertainties.
  Dec 10, 2025
• 3 Stocks Estimated To Be Trading Below Their Intrinsic Value By Up To 46.3%
  As the U.S. stock market navigates a period of uncertainty with investors closely watching the Federal Reserve's upcoming decision on interest rates, major indices like the S&P 500 have recently pulled back after nearing record highs. In this environment, identifying stocks trading below their intrinsic value can be particularly appealing to investors seeking potential opportunities amidst broader market fluctuations.
  Dec 9, 2025
• 3 Stocks Estimated To Be Undervalued In December 2025
  As the Federal Reserve meeting unfolds and major indices like the Dow Jones, S&P 500, and Nasdaq show modest gains, investors are keenly observing how potential interest rate cuts might influence market dynamics. In this environment of cautious optimism and strategic shifts, identifying undervalued stocks becomes crucial for those looking to capitalize on potential market inefficiencies.
  Dec 9, 2025
• Discover 3 Stocks Priced Below Estimated Value
  As the U.S. stock market navigates a period of volatility with major indices like the Dow Jones and S&P 500 experiencing fluctuations ahead of a critical Federal Reserve decision on interest rates, investors are keenly watching for opportunities amidst these shifts. In this environment, identifying stocks that are priced below their estimated value can offer potential advantages, as they may present opportunities for growth when market conditions stabilize or improve.
  Dec 8, 2025
• Freshworks And Two More Stocks Estimated To Be Trading Below Fair Value
  As U.S. stocks rise on hopes of a Federal Reserve rate cut, the market's attention is keenly focused on inflation data and major corporate deals like Netflix's acquisition of Warner Bros. Discovery. In such an environment, identifying undervalued stocks can be crucial for investors looking to capitalize on potential opportunities, as these stocks may offer significant value relative to their current market prices amidst shifting economic conditions.
  Dec 8, 2025
• Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025
  As the U.S. stock market experiences a modest uptick following key inflation data, major indices like the Dow Jones and S&P 500 are nearing all-time highs, reflecting investor optimism despite recent economic uncertainties. In this environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets amid fluctuating market conditions.
  Dec 5, 2025
• Three Stocks That Could Be Undervalued By Market Estimates In December 2025
  As we enter December 2025, the U.S. stock market presents a mixed picture with major indices like the Dow and S&P 500 hovering near all-time highs while investors closely monitor upcoming inflation data that could influence Federal Reserve decisions on interest rates. In this environment, identifying undervalued stocks requires careful consideration of market dynamics and economic indicators, as these factors can reveal opportunities where current valuations may not fully reflect a company's...
  Dec 5, 2025
• 3 Mid-Cap Stocks to Research Further
  Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses will continue prospering by anchoring themselves in unique market segments.
  Dec 4, 2025
• 3 Stocks Estimated To Be Trading Below Their Intrinsic Value
  As major U.S. stock indexes continue to rise, with the Dow Jones Industrial Average nearing a record high despite recent employment concerns, investors are actively seeking opportunities in an evolving market landscape. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential for growth and stability amidst fluctuating economic indicators.
  Dec 4, 2025
• Three Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025
  As the Dow Jones and S&P 500 approach record highs, investors are closely watching market movements amidst expectations of a potential interest rate cut by the Federal Reserve. In this environment, identifying stocks that may be trading below their intrinsic value can offer opportunities for those seeking to capitalize on market inefficiencies.
  Dec 4, 2025
• Listening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
  EDINBURGH, Scotland, December 04, 2025--DexCom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of Dexcom Academy, a new personalised learning platform created with healthcare professionals (HCPs) and for healthcare professionals. The platform is now available in Belgium, Germany, the Kingdom of Saudi Arabia, the Netherlands, and Spain with further EMEA country launches planned for 2026.
  Dec 4, 2025
• Lyft And 2 Other Stocks That May Be Trading Below Fair Value Estimates
  As of early December 2025, U.S. markets have shown resilience with major indexes closing higher amid a rebound in tech and crypto-related stocks. This environment presents opportunities for investors to explore stocks that may be trading below their fair value estimates, such as Lyft and others, by focusing on fundamental strengths and market positioning amidst the current economic landscape.
  Dec 3, 2025
• 3 Stocks Estimated To Be Trading At Up To 43.6% Below Intrinsic Value
  In recent sessions, major U.S. stock indexes have shown resilience, rising despite initial declines due to disappointing private payroll data and adjustments in tech sector sales strategies. As investors navigate these fluctuating conditions, identifying stocks trading below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies.
  Dec 3, 2025
• Is DexCom Stock Underperforming the S&P 500?
  DexCom has considerably underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.
  Dec 3, 2025
• Chagee Holdings And 2 Other Stocks That May Be Priced Below Estimated Value
  As the U.S. stock market experiences slight gains following a pause in its recent upward streak, investors are closely watching the tech and crypto sectors for signs of recovery amid fluctuating sentiment. In this environment, identifying undervalued stocks can be particularly appealing for those looking to capitalize on potential market inefficiencies, with Chagee Holdings and two other companies potentially offering such opportunities.
  Dec 2, 2025
• 3 Stocks Estimated To Be Trading Below Their Intrinsic Value In December 2025
  As December 2025 begins, the U.S. stock market faces a pullback with major indices like the Dow Jones, S&P 500, and Nasdaq closing lower amid a risk-off sentiment affecting big tech and crypto-tied shares. In such an environment, identifying stocks that are potentially trading below their intrinsic value can offer investors opportunities to capitalize on mispricings in the market.
  Dec 2, 2025
• Teradyne upgraded, Circle Internet initiated: Wall Street's top analyst calls
  Teradyne upgraded, Circle Internet initiated: Wall Street's top analyst calls
  Dec 2, 2025
• DexCom Stock Upgraded. How the Glucose Monitor Maker Is ‘Turning a Corner.’
  DexCom has had a rough ride this year. The medical technology company is grappling with concerns about its slowing growth and allegations of faulty blood glucose monitors. Morgan Stanley analyst Patrick Wood upgraded the stock to Overweight from Equal Weight on Tuesday, citing a favorable risk/reward balance moving out of a challenging year for the maker of continuous glucose monitors.
  Dec 2, 2025
• 3 Prominent Stocks Estimated To Be Undervalued By At Least 40.2%
  As December begins, major U.S. stock indexes have slipped, with big tech and crypto-tied shares experiencing declines amid a risk-off sentiment in the market. In this environment, identifying undervalued stocks can be crucial for investors looking to capitalize on potential opportunities that may arise from current market fluctuations.
  Dec 1, 2025
• Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value
  As the U.S. stock market wraps up a strong week, with major indices like the S&P 500 and Dow Jones Industrial Average extending their winning streaks, investors are keenly observing opportunities amid fluctuating tech performances and economic shifts. Despite the Nasdaq's recent monthly dip, this environment presents a chance to explore stocks potentially trading below their fair value, such as Alnylam Pharmaceuticals, which may offer intriguing prospects for those seeking undervalued...
  Dec 1, 2025
• Does DexCom’s Recent 5% Jump Signal a Real Value Opportunity for 2025?
  Wondering if DexCom stock is a hidden bargain or just riding a wave? You are not alone, and today's market swings only add to the intrigue. DexCom shares have jumped 5.4% over the past week even after dropping 6.9% in the last month, and are down 19.1% year-to-date. Recently, the stock has moved in response to industry-wide buzz around new diabetes technology and updates from competitors that are reshaping investor sentiment. Headlines have highlighted both innovation and competitive...
  Nov 28, 2025
• How Investors May Respond To DexCom (DXCM) Balancing Innovative Diabetes Tech Launches With Legal and Regulatory Challenges
  DexCom recently announced the upcoming U.S. launch of its G7 15 Day Continuous Glucose Monitoring system and received FDA clearance for its Smart Basal insulin dosing optimizer, both targeting improved accuracy and convenience for diabetes management in adults. These product advancements arrive as DexCom faces multiple class action lawsuits and regulatory scrutiny related to alleged unauthorized design changes in its G6 and G7 devices, raising questions about reliability and company...
  Nov 28, 2025
• Here’s Why Dexcom (DXCM) Traded Down in Q3
  Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter. A copy of the letter can be downloaded here. U.S. large-cap growth equities continued to recover from a sharp sell-off in early April. Strong corporate earnings, investor enthusiasm around artificial intelligence (AI), and growing expectations for Federal Reserve […]
  Nov 27, 2025
• Carillon Eagle Mid Cap Growth Fund’s Views on Dexcom (DXCM)
  Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the equity markets continued their rally, fueled by enthusiasm for AI, limited evidence of inflationary effects from tariffs, and expectations for further interest […]
  Nov 25, 2025
• Morgan Stanley, Truist Cautious on DexCom (DXCM) Cites Weaker Gross Margins, Modest Q3 Beat
  DexCom Inc. (NASDAQ:DXCM) is one of the best QQQ stocks to buy according to Wall Street analysts. On November 10, Morgan Stanley cut the price target on DexCom to $63 from $89, while maintaining an Overweight rating on the shares. Additionally, on November 3, Truist also lowered the firm’s price target on DexCom to $82 […]
  Nov 25, 2025
• Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know
  A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies.
  Nov 25, 2025
• GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program
  Del Mar, California--(Newsfile Corp. - November 25, 2025) - American Diversified Holdings Corporation (OTCID: ADHC) announced today that GlucoGuard has completed the Level 2 App integration through DEXCOM's Developer Program. The project development is in conjunction with UC Irvine's MADO program through the California Institute for Telecommunications and Information Technology (CALIT2a).The Dexcom Developer Program is a partnership program that allows developers to access Dexcom API and...
  Nov 25, 2025
• Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More
  Pre-Market Stock Futures: The futures are lower on Tuesday after traders kicked off the holiday-shortened trading week with a massive Monday rally, with all major indices finishing the day higher. A combination of an oversold market, a big bounce-back rally on Friday that saw follow-through on Monday, and some positive AI/Data Center/Hyperscaler commentary to help ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, Serv
  Nov 25, 2025
• 2 Healthcare Stocks For Beginner Investors With a 30-Year Time Horizon
  If you're investing for the next 30 years, don't overlook these top stocks.
  Nov 23, 2025
• AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025
• Top 2 Healthcare Stocks Every New Investor Should Know
  These healthcare stocks have long-term and profitable growth runways.
  Nov 21, 2025
• Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States
  SAN DIEGO, November 20, 2025--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1. At initial launch, Dexcom G7 15 Day will be available for users who receive their Dexcom CGM through DME providers. G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM s
  Nov 20, 2025
• DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
  DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 diabetes patients by integrating with the G7 15 day sensor.
  Nov 20, 2025
• Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading
  The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The "Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For
  Nov 20, 2025
• Dexcom (DXCM) Valuation: Assessing Upside After FDA Clearance of Smart Basal Diabetes Device
  DexCom (DXCM) just received FDA clearance for Smart Basal, a new device designed to help adults with Type 2 diabetes optimize their insulin dosing using personalized, real-time sensor data. This notable step forward signals a new phase for the company. See our latest analysis for DexCom. While the FDA clearance for Smart Basal is a milestone, DexCom’s recent stock performance has yet to reflect renewed optimism. The share price sits at $59.73 after a one-year total shareholder return of...
  Nov 20, 2025
• Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes
  SAN DIEGO, November 19, 2025--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy.1 Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as
  Nov 19, 2025
• 3 Reasons We’re Fans of DexCom (DXCM)
  What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many shareholders. This may have investors wondering how to approach the situation.
  Nov 18, 2025
• 2 of Wall Street’s Favorite Stocks on Our Watchlist and 1 Facing Headwinds
  The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
  Nov 17, 2025
• How Recent Developments Are Reshaping the DexCom Investment Story
  DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven by a modest increase in the discount rate and more cautious revenue growth projections. The revision reflects tempered optimism following the company's latest guidance and earnings results. Stay tuned to learn how you can stay informed on future updates and shifts in DexCom's valuation narrative...
  Nov 15, 2025
• Aristotle Atlantic’s Core Equity Strategy Initiated a Position in Dexcom (DXCM) Backed by Its Robust Financial Stability
  Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and attribution analysis. A copy of the letter can be downloaded here. In the quarter, the US equity market rallied, with the S&P 500 Index reaching 8.12%. Bonds also finished higher in […]
  Nov 14, 2025
• Dexcom Reveals Global Diabetes Advocates: New Voices for Diabetes Awareness This World Diabetes Day
  SAN DIEGO, November 14, 2025--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom’s World Diabetes Day campaign.
  Nov 14, 2025
• Winners And Losers Of Q3: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks
  Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.
  Nov 13, 2025
• Frank Sands Reduces Stake in DexCom Inc by 50.4%, Impacting Portfolio by -1.25%
  Insightful Analysis of Frank Sands (Trades, Portfolio)' Third Quarter 2025 13F Filing
  Nov 13, 2025
• Legal and Regulatory Scrutiny Over Device Changes Might Change the Case for Investing in DexCom (DXCM)
  Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring devices, resulting in potential reliability and safety issues and prompting regulatory scrutiny, including a warning letter from the FDA. This legal and regulatory attention grew after reports linked the device changes to health risks, hospitalizations, and deaths, prompting intensified market...
  Nov 13, 2025
• Is It Time to Revisit DexCom After Latest Innovation Headlines?
  Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen mixed momentum lately, climbing just 0.6% over the past week but still down 24.1% year-to-date and 17.8% in the past twelve months. This performance has put value-focused investors on alert. Recent news around DexCom's continued innovation in glucose monitoring technology has kept the company in...
  Nov 13, 2025
• DexCom Stock: Is Wall Street Bullish or Bearish?
  Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.
  Nov 13, 2025
• The Wild Ride That Sent IBD Stock Of The Day Insulet Into An Early Breakout
  Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an early entry.
  Nov 13, 2025
• Carrot Partners with ŌURA and Dexcom to Deliver Deeper Insights and Experiences for Members on Fertility, Family-Building, and Hormonal Health Journeys
  Carrot today announced a partnership with ŌURA, the world's leading smart ring, and Dexcom, the global leader in glucose biosensing, to empower members with actionable, personalized insights that support fertility and family-building goals through the metabolic-fertility program, Sprints. This collaboration combines Carrot's clinical expertise with advanced insights from ŌURA and Stelo by Dexcom, the first FDA-cleared glucose biosensor available without a prescription in the United States, empow
  Nov 12, 2025
• Whoop Is Considering Going Public in the Next Two Years, CEO Says
  Founder and Chief Executive Officer Will Ahmed said the business is well-positioned for an IPO now that it’s broadened its portfolio to include proprietary technology, hardware, software, analytics and other items, such as accessories and apparel. While Ahmed has previously said Whoop is likely to go public, he hadn’t shared when that might happen. “We like to build things ourselves and we really want to build this home of health for our members,” he added.
  Nov 12, 2025
• DexCom Stock Just Fell to a 5-Year Low. Is It a No-Brainer Buy at This Price?
  DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.
  Nov 12, 2025
• Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others
  In the past week or so, renowned investors Carl Icahn and Mario Gabelli led some huge insider buying. These were not the only notable purchases though.
  Nov 12, 2025
• Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
  DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.
  Nov 11, 2025
• Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
  Nov 11, 2025
• 2 Volatile Stocks with Impressive Fundamentals and 1 Facing Headwinds
  Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
  Nov 11, 2025
• 1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street
  Shares are near their lowest levels in five years.
  Nov 11, 2025
• Patient Monitoring Devices Market to be Worth $118.21 Billion by 2033 at CAGR of 10.21% - Grand View Research, Inc.
  The global patient monitoring devices market size is expected to reach USD 118.21 billion by 2033, registering a CAGR of 10.21% from 2025 to 2033, according to a new report by Grand View Research, Inc. This expansion is fundamentally driven by the increasing need to measure and display vital biometric data. This demand stems from three primary factors: the growing geriatric population and rising prevalence of chronic conditions like cardiovascular disease and diabetes, which require continuous m
  Nov 10, 2025
• Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)
  MONTREAL, November 07, 2025--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l’assurance maladie du Québec (RAMQ) for eligible Québecers aged 18 and older living with type 2 diabetes who are treated with intensive insulin therapy (IIT)*.
  Nov 7, 2025

DXCM Reviews

• WallStreetWolf

  Dec 30, 2025

  $DXCM This stock is like a sweet dessert—totally satisfying, but try not to overindulge or you’ll ruin your dinner!

  Buy

• CryptoCoyote

  Dec 30, 2025

  $DXCM Innovation is thrilling, but in this market, the stakes are sky-high. Will the latest advancements translate to success or stumble under pressure? Investors are certainly feeling the heat!

  Buy

• GainsGoblin

  Dec 29, 2025

  $DXCM Keepin' it tight with that health tech, always in the game, fam!

  Buy

• OptionCipher

  Dec 29, 2025

  $DXCM Innovative solutions are great, but healthcare regulations can be a minefield. One wrong move here could lead to a disaster of epic proportions!

  Sell

• GainsOverBrains

  Dec 29, 2025

  $DXCM They’re riding the tech wave in health, looking sharp with that innovation!

  Buy

• BullBrawler

  Dec 29, 2025

  $DXCM Still waiting for this overhyped glucose monitor to deliver real results.

  Sell

• StonkDestroyer

  Dec 28, 2025

  $DXCM Seems promising, but don’t get too attached.

  Buy

• CandleBinary

  Dec 27, 2025

  $DXCM As a leader in diabetes care technology, this company is dedicated to improving quality of life through innovative solutions. Its relentless focus on research and consumer feedback promises to drive substantial future advancements.

  Buy

• StonkKnight

  Dec 27, 2025

  $DXCM Got the tech to keep folks in the know, watch it climb!

  Buy

• CapitalNova

  Dec 27, 2025

  $DXCM Leading the charge in diabetes management technology, this firm remains at the forefront of advancements that improve patient outcomes. Its robust pipeline and dedication to research and development indicate promising future prospects.

  Buy

• StonkDestroyer

  Dec 27, 2025

  $DXCM Constantly chasing tech; good luck keeping up with the competition.

  Sell

• ProfitShade

  Dec 27, 2025

  $DXCM In the health tech lane, always innovatin' and pushin' forward!

  Buy

• VolatilityStrike

  Dec 27, 2025

  $DXCM The advancements in continuous glucose monitoring technology position this organization well within the growing diabetes management market, attracting increasing attention from healthcare professionals.

  Buy

• CodeAndCapital

  Dec 26, 2025

  $DXCM Because keeping tabs on health is cooler with tech—who said monitors can’t be stylish?

  Buy

• BullBrawler

  Dec 26, 2025

  $DXCM Good luck finding anyone impressed by marginal upgrades.

  Sell

• TraderFury

  Dec 25, 2025

  $DXCM In the world of diabetes care, every innovation brings excitement, but the fear of competition rapidly advancing can make you second-guess everything with this one!

  Buy

• Stonks4Days

  Dec 24, 2025

  $DXCM Always in the game, steady hustle keeps it alive.

  Buy

• BearFighter

  Dec 24, 2025

  $DXCM Another overpriced gadget hoping to fool us.

  Sell

• ShortAndProud

  Dec 22, 2025

  $DXCM Got the juice in health tech, it's worth keeping close.

  Buy

• YieldMyth

  Dec 21, 2025

  $DXCM Tech's on the rise, feelin' good about these vibes, ya dig?

  Buy

• RiskWraith

  Dec 20, 2025

  $DXCM As health tech evolves, this company is in the spotlight! The anticipation builds, but so does the risk—can it maintain its edge in a rapidly changing market?

  Buy

• DividendGhost

  Dec 19, 2025

  $DXCM With the relentless demand for diabetes management solutions, this stock could soar or tank like a roller coaster! It's thrilling, but the stakes are massive—hold on tight!

  Buy

• StonkSamurai

  Dec 18, 2025

  $DXCM Life-saving tech on deck, keeping folks in check, big opportunities ahead!

  Buy

• CapitalFrame

  Dec 17, 2025

  $DXCM This company is revolutionizing diabetes management with its advanced technology solutions. Their commitment to improving patient outcomes through innovative products positions them as a leader in the healthcare technology field, with significant growth potential.

  Buy

• LazyQuant

  Dec 16, 2025

  $DXCM They’ve got the tech to keep an eye on your sugar levels. Sweet, right? Just don’t ask them to do your homework!

  Buy

• TradePhantom

  Dec 16, 2025

  $DXCM Diabetes tech? More like tech that can't get out of its own way.

  Sell

• PortfolioFreak

  Dec 16, 2025

  $DXCM Constantly battling the market's ups and downs, their tech must prove it’s worth the investment. With innovations on the horizon, can they hold strong against rivals?

  Buy

• FiscalFrost

  Dec 15, 2025

  $DXCM Known for its commitment to developing cutting-edge glucose monitoring systems, this firm is paving the way for advancements in diabetes care. Its innovative solutions aim to improve patient quality of life significantly.

  Buy

• TradeRebel

  Dec 15, 2025

  $DXCM With diabetes on the rise, their technology is crucial. But with competitors closing in, will they innovate fast enough to stay at the top?

  Buy

• MarginMeme

  Dec 15, 2025

  $DXCM In the health scene, making moves that matter, feelin' good!

  Buy

• TradeGoblin

  Dec 15, 2025

  $DXCM Steady as she goes! This one’s like gold for the health fam.

  Buy

• BearWithMe

  Dec 15, 2025

  $DXCM Buyers absorbing sell orders effortlessly.

  Buy

• ProfitVortex

  Dec 15, 2025

  $DXCM This one's like finding a hidden gem in a thrift store – you just know it's worth more than the price tag!

  Buy

• MarginMythic

  Dec 15, 2025

  $DXCM With tech advancements racing ahead, staying relevant is a cold sweat for this player. The pressure to innovate is intense, and the clock is ticking!

  Buy

• OptionCipher

  Dec 14, 2025

  $DXCM Technology in health is evolving at lightning speed! If you aren't on top of glucose monitoring advancements, you might just miss the next big innovation wave.

  Buy

• TradeReckoner

  Dec 14, 2025

  $DXCM This stock isn't as sweet as its tech claims to be.

  Sell

• VolatilityStrike

  Dec 13, 2025

  $DXCM With its innovative devices revolutionizing diabetes management, this organization is essential in improving patient outcomes. Its continuous advancements position it as a vital player in the healthcare technology landscape.

  Buy

• TheRiskDealer

  Dec 13, 2025

  $DXCM As the demand for diabetes management solutions rises, the stakes couldn't be higher. Will this company rise to the occasion or be left behind in the dust?

  Buy

• AlgoAce

  Dec 13, 2025

  $DXCM Bullish dominance very clear.

  Buy

• BullRunBoi

  Dec 13, 2025

  $DXCM Sell volume dominating heavily.

  Sell

• ProfitVortex

  Dec 12, 2025

  $DXCM This stock is like your friend who always remembers to bring snacks to the party – super reliable and keeps you feeling your best!

  Buy

• CryptoCoyote

  Dec 12, 2025

  $DXCM Upward pressure not slowing down.

  Buy

• WallStreetGrim

  Dec 12, 2025

  $DXCM Ideal momentum environment for bulls.

  Buy

• MarketNomad

  Dec 12, 2025

  $DXCM Bullish volume spike caught my attention.

  Buy

• BuyLowBro

  Dec 12, 2025

  $DXCM Price action extremely lopsided.

  Sell

• LiquidKnight

  Dec 11, 2025

  $DXCM Cutting-edge tech that’s making waves, yet the pressure to stay ahead can be overwhelming. Will they rise or will they fall behind? It’s a tense game.

  Buy

• ChartNomad

  Dec 11, 2025

  $DXCM The pressure is on as this company navigates fierce competition! Will it rise to the challenge or falter under the weight of expectations? The clock is ticking!

  Sell

• CapitalVortex

  Dec 11, 2025

  $DXCM Innovation and competition clash spectacularly in the health sector. This stock is either poised for an explosive leap or a steep dive – brace yourself!

  Buy

• FiscalFury

  Dec 11, 2025

  $DXCM They’re monitoring glucose levels like hawks—if only my friends could monitor their snack choices as well!

  Sell

• TradePulse

  Dec 11, 2025

  $DXCM Uptrend looks clean and sustainable.

  Buy

• TrendScript

  Dec 11, 2025

  $DXCM Buyers dominating across the board.

  Buy

• CapitalRush

  Dec 11, 2025

  $DXCM Worsening technical conditions.

  Sell

• WallStreetWraith

  Dec 11, 2025

  $DXCM Momentum showing no signs of slowing.

  Buy

• HedgeMeNot

  Dec 11, 2025

  $DXCM Bearish multi-timeframe confluence.

  Sell

• TradeBlaze

  Dec 11, 2025

  $DXCM Bullish price action tightening.

  Buy

• TrendHunter

  Dec 10, 2025

  $DXCM A glucose monitor? How exciting... said nobody ever.

  Sell

• TrendStalker

  Dec 10, 2025

  $DXCM A leader in diabetes tech, but are they leading to anywhere good?

  Sell

• FinTechNomad

  Dec 9, 2025

  $DXCM As innovation races ahead in the health tech space, the pressure to keep up is immense. Falling behind feels like a real risk in this fast-paced environment!

  Buy

• BullishCraze

  Dec 9, 2025

  $DXCM Supply zones rejecting price sharply.

  Sell

• QuantKnight

  Dec 9, 2025

  $DXCM Market leaning heavily negative.

  Sell

• YieldHunter

  Dec 9, 2025

  $DXCM Money flow turning strongly positive.

  Buy

• OptionMatrix

  Dec 9, 2025

  $DXCM This technology-driven firm is revolutionizing diabetes management through innovative monitoring solutions. Their focus on advancing patient care is commendable, and ongoing developments may significantly enhance their market position.

  Buy

• AlphaWave

  Dec 8, 2025

  $DXCM What a whirlwind! Just when you think you’ve got it figured out, the tides turn! Parsing through the chaos is a challenge, but it’s got the fire to ignite interest!

  Buy

• BearMarketSurvivor

  Dec 8, 2025

  $DXCM They’re the real deal, keeping us healthy with tech that counts.

  Buy

• TradeNinja

  Dec 7, 2025

  $DXCM Diabetes tech sounds high-stakes, like balancing your phone on a tightrope. Let’s hope they don’t drop the ball!

  Sell

• DividendDemon

  Dec 6, 2025

  $DXCM They’re monitoring health like a watchful mom with a snack bar—always ready to jump in when needed!

  Buy

• GainMachine

  Dec 6, 2025

  $DXCM When you monitor glucose levels better than your friends monitor their social media likes, you know you've got a winner!

  Buy

• RiskWraith

  Dec 6, 2025

  $DXCM The diabetes management market is booming, but with so many players, can they maintain their edge? Each innovation is a gamble with high stakes, and the clock is ticking!

  Buy

• CapitalCarnage

  Dec 6, 2025

  $DXCM This company is just riding the hype train—good luck with that.

  Sell

• AlphaDruid

  Dec 6, 2025

  $DXCM In the race for health technology, every second matters. This company is in the spotlight, and investors are on edge waiting for the next breakthrough. Can they deliver when it counts the most?

  Sell

• GainMachine

  Dec 6, 2025

  $DXCM They’re all about keeping tabs on glucose, making sure you stay sweet without the sugar rush. Talk about a balanced lifestyle!

  Buy

• EarningsEcho

  Dec 5, 2025

  $DXCM This company’s like your best friend who always knows when to remind you to check your blood sugar levels. Talk about dependable!

  Buy

• TradePredator

  Dec 3, 2025

  $DXCM Chasing growth in a crowded market? Good luck with that.

  Sell

• QuantQuest

  Dec 3, 2025

  $DXCM If this stock were a health trend, it would be kale—everyone loves it, but I still can't figure out how to eat it!

  Buy

• CapitalHex

  Dec 3, 2025

  $DXCM Not a friendly chart for bulls.

  Sell

• ByteBull

  Dec 3, 2025

  $DXCM If this stock were a superhero, it’d be Captain Consistency—saving the day with reliable performance every time!

  Buy

• DividendDemon

  Dec 3, 2025

  $DXCM This company is like the cool kid in health tech—always on the cutting edge and making diabetes management stylish!

  Buy

• StonkKnight

  Dec 2, 2025

  $DXCM Stayin' sharp in health tech, always on point with innovation.

  Buy

• VolatileViking

  Dec 1, 2025

  $DXCM This one monitors your health better than your mom! They might just need a 'health freak' award.

  Buy

• MarginMythic

  Dec 1, 2025

  $DXCM The demand for innovative diabetes care solutions is surging, but can this company keep pace with the rapid evolution in technology and patient expectations?

  Buy

• TickerTakedown

  Dec 1, 2025

  $DXCM This stock is like the cool kid at school—always in style and never fails to impress!

  Buy

• ProfitVortex

  Dec 1, 2025

  $DXCM This company is basically the superhero of glucose monitoring. Just imagine capes and meters working together to save the day!

  Buy

• TheTradingVerse

  Nov 30, 2025

  $DXCM With its cutting-edge technology that enhances diabetes management, this firm is making significant strides in healthcare. As more patients seek reliable solutions for chronic conditions, their products could see expanded adoption and recognition.

  Buy

• YieldHunter

  Nov 30, 2025

  $DXCM This organization stands out for its groundbreaking contributions to diabetes care technology. Its commitment to improving patient outcomes positions it as a leader in a critical healthcare niche.

  Buy

• FiscalEngine

  Nov 30, 2025

  $DXCM With its focus on diabetes management solutions, this organization addresses an urgent healthcare need through cutting-edge technology. Their commitment to innovation and patient care could drive their continued success.

  Buy

• ChartFang

  Nov 29, 2025

  $DXCM At the forefront of diabetes care technology, this company is making significant strides in improving patient outcomes. Their continuous innovation reflects a strong commitment to enhancing healthcare experiences, which could drive future growth.

  Buy

• TheRiskDealer

  Nov 29, 2025

  $DXCM With the healthcare stakes incredibly high, innovation is critical. Every new device could mean life or death; the pressure to deliver is relentless and unforgiving!

  Buy

• MarginBeast

  Nov 29, 2025

  $DXCM Just another overpriced tech toy with a shiny facade.

  Sell

• ShortCircuit

  Nov 29, 2025

  $DXCM This one's just a sugar-coated disappointment.

  Sell

• DividendVortex

  Nov 29, 2025

  $DXCM This company continues to innovate in the diabetes care market, making significant strides in continuous glucose monitoring technology. Their commitment to improving patient outcomes is commendable, and their latest product launches indicate a strong pipeline ahead.

  Buy

• MarginBeast

  Nov 29, 2025

  $DXCM DexCom: because who needs steady profits anyway?

  Sell

• RiskVandal

  Nov 28, 2025

  $DXCM They claim to innovate, but the only thing innovative is their ability to annoy.

  Sell

• LazyQuant

  Nov 28, 2025

  $DXCM The stock equivalent of your friend who always remembers your birthday. Sweet and dependable!

  Buy

• ShortRaid

  Nov 28, 2025

  $DXCM With a commitment to enhancing diabetes management through cutting-edge technology, this firm is improving patient outcomes. Its growth potential in a niche market is impressive.

  Buy

• TradeBlitz

  Nov 28, 2025

  $DXCM This biz is like your best buddy at a party—the one who always has the gadget to keep the vibe just right, especially for the sweet-toothed!

  Buy

• GainSurge

  Nov 28, 2025

  $DXCM Navigating through the unpredictable waves of the healthcare market, this company is at the forefront of technology that's transforming lives. The tension is palpable as competitors linger, eager to capitalize on any misstep.

  Buy

• StonkSlayer

  Nov 28, 2025

  $DXCM This stock is like a great meme—trendy, attention-grabbing, and everyone’s talking about it—but will it last longer than a viral trend?

  Buy

• ProfitVortex

  Nov 28, 2025

  $DXCM More reliable than your WiFi signal during a Netflix binge—this one's got my attention for sure!

  Buy

• DividendVandal

  Nov 28, 2025

  $DXCM An industry leader in continuous glucose monitoring, this company continues to push the boundaries of diabetes management technology. Their relentless focus on innovation positions them well for sustained market leadership.

  Buy

• QuantAssault

  Nov 28, 2025

  $DXCM This company is like the superhero of glucose monitoring! Capes and gadgets not included, but who doesn't love being health-savvy?

  Buy

• ProfitLancer

  Nov 28, 2025

  $DXCM In a sea of competitors, this one's just treading water.

  Sell

• FiscalFury

  Nov 27, 2025

  $DXCM Imagine a gadget that not only tells you the time but also makes your coffee—it’s just that extra level of awesome!

  Buy

• WallStreetBandit

  Nov 27, 2025

  $DXCM Just another health tech trying to get under your skin.

  Sell

• TradeBlitz

  Nov 27, 2025

  $DXCM When it comes to health tech, this company is basically the wizard behind the curtain—making life a little less wizardly scary!

  Buy

• MarginDagger

  Nov 27, 2025

  $DXCM Pioneering continuous glucose monitoring technology, this firm is at the forefront of diabetes management. With increasing awareness and adoption of its solutions, it is set to play a key role in improving patient outcomes.

  Buy

• BearEater

  Nov 25, 2025

  $DXCM A pioneer in diabetes care technology, this company continues to push the boundaries of innovation. Its advanced monitoring systems not only enhance patient experience but also position it as a leader in a critical and expanding healthcare market.

  Buy

• PriceBreaker

  Nov 25, 2025

  $DXCM This firm is revolutionizing diabetes management with cutting-edge continuous glucose monitoring systems, which are gaining traction among both patients and healthcare providers. Their commitment to improving patient outcomes is commendable.

  Buy

• TradeFrenzy

  Nov 25, 2025

  $DXCM This one keeps missing the mark, just like your last New Year's resolution.

  Sell

• IndexPredator

  Nov 25, 2025

  $DXCM The relentless rise of diabetes cases makes this company a frontrunner, yet competition lurks around every corner—will they maintain their edge or falter in the frenzy of innovation?

  Buy

• StonkSlayer

  Nov 23, 2025

  $DXCM Keeping diabetes in check like a pro! Let’s just hope it doesn’t get too dramatic!

  Buy

• ProfitLancer

  Nov 23, 2025

  $DXCM They talk a big game, but where's the proof?

  Sell

• OptionOverlord

  Nov 23, 2025

  $DXCM If glucose monitoring were a sport, this company would take home the gold. Just imagine those tiny athletes on the glucose track!

  Buy

• GammaSlayer

  Nov 22, 2025

  $DXCM Diabetes tech that’s stuck in the past and losing ground.

  Sell

• RiskAssassin

  Nov 22, 2025

  $DXCM This company's advancements could either redefine the industry or leave them in the dust if they can't keep pace. The stakes have never felt higher!

  Buy

• Stonks4Days

  Nov 22, 2025

  $DXCM In the health game, watch it rise like a boss!

  Buy

• TickerTyrant

  Nov 22, 2025

  $DXCM Continuous glucose monitoring? More like continuous disappointment.

  Sell

• BuyLowBro

  Nov 21, 2025

  $DXCM This stock is like your overachieving friend who always brings home top grades. Seriously, how do they do it?

  Buy

• TradeBlitz

  Nov 21, 2025

  $DXCM Monitoring your health like a hawk! Just don’t let it get jealous of your snack cabinet—it might send you reminders!

  Buy

• CashCombo

  Nov 21, 2025

  $DXCM When your glucose monitor is more dramatic than your soap opera—plot twist! 📺

  Buy

• YieldMyth

  Nov 20, 2025

  $DXCM Staying sharp in the health game, these folks are on to something!

  Buy

• HODLWarrior

  Nov 19, 2025

  $DXCM Rising like bread, this baby’s cooking up something real good, don't sleep!

  Buy

• VolatileViking

  Nov 19, 2025

  $DXCM This company knows how to keep things sweet, even if you're trying to avoid sugar. It's like a health-obsessed friend who never stops offering you kale smoothies!

  Buy

• AlphaStriker

  Nov 18, 2025

  $DXCM Managing diabetes is tough; investing here is tougher.

  Sell

• ShortCircuit

  Nov 18, 2025

  $DXCM Sure, they have a product. Too bad it’s overpriced junk.

  Sell

• AlphaVandal

  Nov 18, 2025

  $DXCM Glorified band-aid solutions; innovation is not their forte.

  Sell

• YOLOTrader

  Nov 17, 2025

  $DXCM This stock’s like a glucose monitor—always keeping tabs on the highs and lows, but way more exciting!

  Buy

• MarketNomad

  Nov 17, 2025

  $DXCM Diabetes tech? Sounds cool until you check the price tags.

  Sell

• EarningsSync

  Nov 16, 2025

  $DXCM This company dances between groundbreaking advancements and potential pitfalls! Every innovation is a gamble—will it pay off or crash? My anxiety is through the roof!

  Buy

• ProfitVandal

  Nov 16, 2025

  $DXCM Following this stock is like chasing a moving target.

  Sell

• BullRunBoi

  Nov 15, 2025

  $DXCM Diabetes tech on point, life-changing gadgets in the mix!

  Buy

• QuantSpecter

  Nov 15, 2025

  $DXCM With advancements in diabetes care, this stock seems positioned for a breakthrough! But can it navigate the complex landscape without faltering? It’s a nail-biter!

  Buy

• GainsOverBrains

  Nov 15, 2025

  $DXCM This joint's got mad potential, keep your eyes peeled for those sweet gains!

  Buy

• StockSpecter

  Nov 14, 2025

  $DXCM Catching diabetes profits like a leaky faucet.

  Sell

• RiskRanger

  Nov 14, 2025

  $DXCM Tech so sharp, it’s basically the superhero of health monitoring—saving lives, one glucose level at a time!

  Buy

• TradeBlitz

  Nov 13, 2025

  $DXCM When it comes to diabetes tech, this company is hitting all the right notes—let’s just hope it avoids sour notes!

  Buy

• GainSurge

  Nov 13, 2025

  $DXCM This stock is a rollercoaster right now! New developments promise to shake things up, but can they handle the spikes and drops? It's a nail-biter for investors!

  Buy

• EquityPulse

  Nov 12, 2025

  $DXCM With the healthcare sector evolving rapidly, this company is on a tightrope! Innovation is key, but can they keep up with the pace and satisfy the growing demand without losing their footing?

  Sell

• WallStreetGrim

  Nov 12, 2025

  $DXCM This company is a leader in diabetes management solutions, continuously innovating with cutting-edge technology that improves patient outcomes. Their strategic initiatives and expanding product pipeline showcase a commitment to enhancing the quality of life for individuals with chronic conditions.

  Buy

• CandleBinary

  Nov 10, 2025

  $DXCM This company has established itself as a leader in continuous glucose monitoring technologies, significantly enhancing diabetes management. Their strong market presence and commitment to research and development suggest a bright future as health technology continues to evolve.

  Buy

• MarketMemeLord

  Nov 10, 2025

  $DXCM With the tech they got, they’re sweetening the deal for diabetics!

  Buy

• IndexPredator

  Nov 9, 2025

  $DXCM This tech giant is in the spotlight, but with intense competition breathing down its neck, the stakes have never been higher! Investors are on edge, watching closely to see if it can maintain its edge in this fast-paced market.

  Buy

• TrendStalker

  Nov 9, 2025

  $DXCM Health tech, but you’re just a tick off the pulse.

  Sell

• TradeGoblin

  Nov 8, 2025

  $DXCM Always on the pulse, these folks keep it real in diabetes tech.

  Buy

• ChartFang

  Nov 7, 2025

  $DXCM With continuous advancements in diabetes management solutions, this company is at the forefront of providing essential technology that improves patient outcomes. The integration of cutting-edge devices and data analytics showcases its dedication to revolutionizing the healthcare landscape, making it a noteworthy player in the market.

  Buy

• HedgeMeNot

  Nov 3, 2025

  $DXCM tight ouch clear steady spike volume charts tight charts wild feels hedges no session charts loud theta bagholder dead noise smart theta nasty broken watching levels

  Sell

• TendieTitan

  Oct 29, 2025

  $DXCM no hurts tape steady feels tax on earnings here hedges tax flows volume range today whispers imo spike trigger keeping wild nasty breakout earnings oversold hurts queued heater clear risk

  Buy

• ShortSqueezeX

  Oct 21, 2025

  $DXCM keeping macro imo hurts fire tbh volume nasty heavy mode uptrend watching sentiment clean steady trigger level-to-level buzzing heavy here tape steady sentiment fast charts tbh money volume

  Buy

• ProfitVortex

  Oct 12, 2025

  $DXCM meeting looks trap liquidity like bagholders a soon

  Sell

• ShortCircuit

  Oct 11, 2025

  $DXCM nimble today volume rough today wild noise broken eyes hands steady range now imo maybe mode wick supply it today bagholder hurts mode hurts levels buzzing

  Sell

• BullRunBandit

  Oct 8, 2025

  $DXCM now uptrend tbh buzzing charts strong keeping on grind mooning feels theta flows heavy now charts

  Buy

• DiamondHands

  Oct 7, 2025

  $DXCM diamond noise here tax tape spike money grind loud printing noise spicy charts diamond today trend oversold bull

  Buy

• OptionNomad

  Sep 26, 2025

  $DXCM This chart looks like it just had an energy drink. Green candles hitting.

  Sell

• FiscalBinary

  Sep 24, 2025

  $DXCM spike tbh clean steady talking tax risk flows nimble maybe levels volume range it whispers printing soon flows today keeping go wild

  Buy

• CodeTrader

  Sep 23, 2025

  $DXCM macro macro hurts nasty noise theta range tax mode talking macro heavy on tape spike heat bounce hedges earnings diamond crushing now diamond macro loud uptrend

  Buy

• ChartFang

  Sep 22, 2025

  $DXCM This setup is giving main character energy. I'm not saying it's mooning, but it's definitely packing.

  Sell

• CashKiller

  Sep 18, 2025

  $DXCM hard clear soon smart mode today it here grind clean no nimble smooth trigger sentiment mode strong maybe run trigger earnings heavy tape queued beastly diamond spike flows it fire

  Buy

• IndexPredator

  Sep 18, 2025

  $DXCM If patience was a stock, I'd be rich by now. Someone please.

  Sell

• ProfitShade

  Sep 15, 2025

  $DXCM soon macro soon tbh it tbh bagholder my headfake spike feels eyes loud loud steady

  Sell

• MarketReaper

  Sep 14, 2025

  $DXCM soon-ish sauce smart heavy ouch my steady mode charts tape fading grind keeping earnings nimble wall

  Sell

• SignalStriker

  Sep 9, 2025

  $DXCM mode it tax level-to-level levels tape humming theta patience now heating go on hurts mode staying wild hard grind on clear hard check range maybe noise money money steady eyes

  Buy

• MissionOverlord

  Sep 4, 2025

  $DXCM winter trend's deader and than

  Sell

• TickerPhantom

  Sep 4, 2025

  $DXCM in falling gets GPA bounce my faster than operas instantly I've recoveries sold every

  Sell

• StonkViking

  Sep 1, 2025

  $DXCM Perfect setup for disappointment right here. My portfolio's new hobby:.

  Sell

• DividendGhost

  Aug 30, 2025

  $DXCM soon-ish levels trigger hands fast steady ouch tax wild talking soon queued range nimble macro soon heavy weak grind supply today volume mess tape candle soon

  Sell

• HODLWarrior

  Aug 26, 2025

  $DXCM a even rally fake can't

  Sell

• ProfitVortex

  Aug 20, 2025

  $DXCM Feels like watching a roller coaster designed by interns. Bulls and bears are just.

  Buy

• MarginMyth

  Aug 18, 2025

  $DXCM watching money spike here oversold tape today clean gains no king clear beastly momentum level-to-level nasty buzzing smart tape steady hands theta on charts soon soon

  Buy

• TrendScript

  Aug 13, 2025

  $DXCM faster investors GPA deserve like falling than smells pay

  Sell

• YieldHunter

  Aug 11, 2025

  $DXCM winter deader trend's crypto than

  Sell

• BagholderPrime

  Aug 10, 2025

  $DXCM bull breakout patience queued rocket printing charts spike tight oversold money vibes

  Buy

• OptionCipher

  Jul 11, 2025

  $DXCM smart move imo fire watching nimble spicy wild charts clean trend spicy tape

  Buy

• ShortSavage

  Jul 6, 2025

  $DXCM bid feels vibes clear tax clear tbh feels ath clear king frankly range uptrend queued humming uptrend dripping

  Buy

• MoneyMage

  Jun 26, 2025

  $DXCM fast hands watching cat bagholder tbh hurts tbh sauce charts spike supply out tax ouch

  Sell

• TradePredator

  May 7, 2025

  $DXCM steady lower ruggy rip sauce trigger mess money levels candle rough macro

  Sell

• StockNova

  Mar 28, 2025

  $DXCM money whoa humming levels noise oversold heat sentiment rocket now crushing

  Buy

• MarginBeast

  Mar 20, 2025

  $DXCM fire pumping queued wild tbh uptrend fast nasty watching charts clean trigger charts

  Buy

• PnLReaper

  Oct 13, 2024

  $DXCM whoa now look today headfake wild clean trap soon eyes stops macro dive wild headfake

  Sell

• StonkZombie

  Oct 4, 2024

  $DXCM heater run maybe hard energy frankly today soon-ish pumping clear on earnings mooning no nasty today crushing

  Buy

• Stonks4Days

  Sep 28, 2024

  $DXCM printing king oversold feels and hurts hands tight earnings heater

  Buy

• CapitalRush

  Sep 23, 2024

  $DXCM bid vol earnings loud buzzing run bounce hedges heavy theta printing dripping theta tax heavy

  Buy

• ByteBull

  Sep 9, 2024

  $DXCM session soon noise mode session buzzing tape hurts tax hands here stops tax mode fading diamond tbh maybe session level-to-level

  Sell

• FinTechFrost

  Sep 8, 2024

  $DXCM tight no here tbh soon soon-ish nasty check crushing no check tight tax today beastly whoa now keeping sentiment go

  Buy

• GammaSlayer

  Jun 19, 2024

  $DXCM tape money fire soon hard talking now rocket on heat today trigger flows clean

  Buy

• BullRunBoi

  Apr 25, 2024

  $DXCM tbh run uptrend hands tax energy heating smooth strong feels gains today earnings

  Buy

• ShortSavior

  Mar 31, 2024

  $DXCM go breakout mode whispers trigger move nimble here nasty check tight whispers hedges smooth money gains

  Buy

• DiamondHandz

  Jan 5, 2024

  $DXCM macro diamond whoa tax dumping heavy macro talking soon charts city trigger on levels hedges bear heating soon-ish keeping weak

  Sell

• WallStreetGrim

  Dec 19, 2023

  $DXCM spike hands passed range uptrend fast talking humming staying noise alpha level-to-level on uptrend

  Buy